New Video following poster presentation at the European Lung Cancer Congress 2025

We are pleased to share a video presentation by Prof. Em Johan Vansteenkiste (University Hospitals Leuven, Belgium), the principal investigator of our clinical trial PDC-LUNG-101 with PDC*lung01, our innovative, "off-the-shelf" therapeutic cancer vaccine for non-small cell lung cancer (NSCLC).

 Recorded at the European Lung Cancer Congress in Paris on March 28th, Prof. Vansteenkiste discusses:
✅ The clinical and immune results from the ongoing trial
✅ The key advantages of our allogeneic dendritic cell-based cancer vaccine, PDC*lung01

This presentation offers an insightful perspective on the promise of our immunotherapy approach.

Watch the video on MediMix Oncology:  https://lnkd.in/eTiZbFaM

Video Overview from MediMix Oncology:

In this video, Prof Em Johan Vansteenkiste, thoracic oncologist, shares the primary results of a phase I/II study evaluating the PDC*lung01 (IMP) cancer vaccine. This vaccine is based on irradiated plasmacytoid dendritic cell line loaded with 7 HLA-A*02:01-restricted tumor peptides. In the presented study, 73 HLA-A*02:01 positive NSCLC patients received IMP either at low (cohort A1) or high dose (cohort A2) in the adjuvant setting (resected stage II/IIIA), and either at low (cohort B1) or high dose (cohort B2) in combination with pembrolizumab (200 mg q3w) in untreated patients with stage IV disease and a PD-L1 expression ≥50%. 

In cohort B2 of the study, a confirmed objective response rate (ORR) of 55% was reported, with a median progression-free survival (PFS) of 8.87 months. Interestingly, this corresponds to a 16% increase in ORR and a 2.4-month improvement in median PFS, compared to the results obtained with pembrolizumab monotherapy in Keynote-042. Furthermore, the vaccine came with a mild safety profile. Finally, the investigators reported a correlation between the intensity of the immune response and the PFS.
References: Vansteenkiste J et al. ELCC 2025. Abstract 21P.